Established in 2003, Diagnoptics is the pioneer of cutting edge diagnostic devices that enable clinicians to non-invasively assess cardiovascular risk and diabetes risk. Its technological advance in detecting the autofluorescence of Advanced Glycation Endproducts (AGEs) in skin tissue has led to the invention of the AGE Reader – a state of art non-invasive medical device that allows the determination of the tissue accumulation of AGEs within 12 seconds.

AGEs are essential biomarkers of metabolic and glycemic stress and have been implicated as causative factors in the progression of a host of age-related diseases, such as chronic kidney disease, diabetes, atherosclerosis, and Alzheimer’s. The amount of AGEs in tissue serves as an important risk predictor for a vast array of chronic conditions like cardiovascular complications and for diabetes and its complications as well as for premature aging.

Mission

Diagnoptics’ mission is to provide clinicians as well as complementary and alternative medicine professionals with state of the art technology for the non-invasive assessment of tissue glycation and to improve the standard of care of (cardiovascular) risk assessment and healthier living for longer.